



Webinar will begin promptly at:  
11 AM ET / 4 PM GMT



# ISMPP University

Coronavirus (COVID-19):



## Its Impact on Publication Planning

April 29, 2020





# ISMPP Would Like to Thank...

... the following Titanium and Platinum Corporate Sponsors for their ongoing support of the Society:



# ISMPP U Sponsor Opportunity

---

If you are interested in sponsoring a future ISMPP U, please visit <https://ismpp.memberclicks.net/ismpp-u-sponsorship>



**BECOME A  
SPONSOR**



# Save the Date for the 16th Annual Meeting!

A promotional graphic for the Virtual 16th Annual Meeting of ISMPP. The background shows a person's silhouette looking at a laptop displaying a video conference grid. Text overlays include: "Virtual 16th Annual Meeting of ISMPP June 16-18, 2020" in green, "Save the Dates!" in blue, and "Registration Opens April 30!" in blue. A small ISMPP logo is in the bottom left corner.

Virtual  
16th Annual Meeting of ISMPP  
June 16-18, 2020

Save the Dates!

Registration Opens April 30!





International Society for Medical Publication Professionals



# Upcoming ISMPP U's – 16<sup>th</sup> Annual Mtg Previews!

Don't miss your opportunity to sample the excellent content from the upcoming ISMPP virtual Annual Meeting

DATE	TOPIC	FACULTY
May 20, 2020 	<i>Bite-size content: reaching physicians in a time-poor era of information overload</i>	Richard Ashdown, McCann Health Medical Communications  Joanne Walker, Future Science Group  Beth Whann, Pfizer  Mary Gaskarth, CMC Affinity
May 27, 2020 	<i>Data privacy protection: Which wayforward?</i>	Jon Bigelow, Coalition for Healthcare Information



# **ISMPP VOLUNTEER DRIVE IS OPEN THRU APRIL 30!**


**To sign-up, visit:**

**[www.ismpp.org/committees](http://www.ismpp.org/committees)**



# Get Connected!

#ISMPP



The screenshot shows the ISMPP website homepage. At the top right, there are links for "Contact Us", "Terms and Conditions", and "Sign In". The main navigation bar includes "HOME", "COMMUNITIES", "DIRECTORY", "EVENTS", "BROWSE", and "PARTICIPATE", along with a search bar. The central banner features the text "LET'S CONNECT!" over a network graphic. Below the banner, there are three main sections: "Latest Discussions", "Recent Shared Files", and "Upcoming Events".

Latest Discussions	Recent Shared Files	Upcoming Events
<p>Post to this Discussion This Discussion has no recent posts. Your new post to this Discussion will display here and be sent via email to subscribed Community members.</p> <p><a href="#">Post to this Discussion</a></p>	<p>Create a Library Entry This Library has no recent entries. Add a file or multimedia through a new Library Entry.</p> <p><a href="#">Create a Library Entry</a></p>	<p><b>20</b> 10th Annual Meeting of ISMPP APRIL Apr 20 - 22 (ET) Washington, DC, United States</p>




# CMPP Announcements

---

- Nominations for the 2020-2021 Certification Board are due May 15, 2020
- Digital Badges (Certificates) coming soon to all CMPPs!  
Check out <https://www.ismpp.org/cmpp-digital-badges> for more information







# For Your Best ISMPP U Experience...

---

## To optimize your webinar experience today:

- Use a hardwired connection if available
- Use the fastest internet connection available to you
- If you are accessing the presentation over your computer, please be sure to increase the volume of your computer speakers



# Questions

- To ask a question, please type your query into the Q&A box
- To ensure anonymity and that all presenters receive your question, please choose the drop down box option:

**"Host & Presenters"**

Otherwise, all audience members will be able to see your submitted question


- We will make every effort to respond to all questions

1. Click on the question mark to view the Q&A box

2. Type your question into the Q&A box and SEND

**NOTE: Make sure you send your question to: "Host & Presenters"**

The screenshot displays the Zoom meeting interface. At the top right, a red box highlights a question mark icon. A red arrow points from this icon to the Q&A box. The Q&A box is open, showing a question from Laine Capaccio: "Q: can you see my q&a?". Below the question, the "Ask:" dropdown menu is set to "Host & Presenters". A red arrow points from the "Send" button in the Q&A box to the "Send" button in the "Ask:" dropdown menu.



# Speakers



**Katy Amberley**, BA, MA, Chief Executive, British Society for Haematology (BSH)




**Jason Gardner**, BSc, PhD, ISMPP CMPP™, Head of Scientific Services, CMC Connect, McCann Health Medical Communications



**Moderator:**  
**Carolyn Hustad**, PhD, Associate Vice President, Merck & Co.



**Maria Khan**, BSc, Senior Editorial Director for Health Sciences, Wiley



# Speakers



**Robert Matheis, PhD, MA,**  
President & Chief Executive Officer,  
International Society for Medical  
Publication Professionals (ISMPP)




**Alex Torre-Tasso, Global Business  
Unit Head, Envision Pharma Group**



**Tyson Tu, PhD, Director, Global  
Medical Communications, Vertex**




**Chris Winchester, PhD, Chief  
Executive Officer, Oxford  
PharmaGenesis**



# Disclaimer

---

- Information presented reflects the personal knowledge and opinion of the presenters and does not necessarily represent the position of their current or past employers or the position of ISMPP



# Learning Objectives

---

At the end of this session, attendees should be able to

- Be knowledgeable of challenges to medical publishing stemming from the Coronavirus (COVID-19) pandemic
- Be aware of how congresses and journal publishers are being affected
- Modify publication plans appropriately in response to changing conditions
- Maintain good publication practices and ethics in a rapidly shifting environment



# Survey: Work Disruptions Due to COVID-19

---

334 Responses

93.98% of respondents indicated their work has been disrupted by COVID-19.

61.67% indicated greatly/moderately impacted



## Official Guidance on Authorship of Peer-review Publications in Which Coronavirus Disease Has Impacted Author Responsiveness

**Robert J. Matheis, PhD, MA**  
**President and CEO**  
**ISMPP**






# Survey: Author Responsiveness Impacted

83.52% of survey respondents indicated authorship issues related to COVID-19



Some respondents noted an *increase* in responsiveness if the author does not work directly on COVID-19 patients or cannot work due to building closures




# Steering Committee

---

- Meera Kodukulla
- Sonia Schweers
- Michelle Carfagno
- Beth Whann
- Merry Saba
- Carolyn Hustad
- Stephanie Brown
- Susan Hannah
- Catherine Skobe
- Avishek Pal





# Helping Publication Professionals Through Unusual Times

## Authors have become non-responsive

- Fallen ill
- Quarantined
- Caring for patients



## Important Research to be Published

- Pivotal data awaits publication
- Science needs to progress
- Patient care is at stake





## What do we do?

---



Do I **Wait** for a bit?

Do I Just **Submit**?

Do I do **Nothing**?



## ISMPP Provides a Guidance



Time-sensitive research



Non-responsiveness would **delay the communication** of science



An Author Has Become **Non-Responsive**



There is a reason to suspect **COVID-19**




## What about ICMJE?

---

1. **Substantial contributions** to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. **Drafting** the work or **revising** it critically for important intellectual content; AND
3. **Final approval** of the version to be published; AND
4. Agreement to be **accountable** for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.






# Principles of our Guidance

---

1. ICMJE Criterion #1 and Criterion #2 MUST ALWAYS be Achieved
2. Author Consensus
3. Transparency with the Journal
4. Journal Decision Making




# Principles of our Guidance

---

## Recommendations: Authors

1. Following a reasonable period of **documented attempts** to reach the author, **proceed with submission** to the peer-review journal or congress, **including the affected individual** as a byline author who has previously achieved ICMJE Criterion 1 and ICMJE Criterion 2.
2. It is understood that inclusion of the individual as an author shall be **agreed upon by all authors** who have fully met the four ICMJE Criteria.
3. It is further understood that the work can be submitted provided that **other authors approve** the publication and accept responsibility for the work, as is required by ICMJE Criterion 4.






# Principles of our Guidance

---

## Recommendations: Journal

1. As a matter of full disclosure, provide an **accompanying statement** to the journal or congress to transparently represent that ICMJE Criterion #3 and/or Criterion #4 were not fully achieved by the affected author.
2. Medical journal editors and congress officials have the discretion to determine and **elect a disposition** for the submission, including:
  - 1) accept
  - 2) reject
  - 3) adaptation of the byline, and/or
  - 4) publication of a qualifying statement related to authors




# Principles of our Guidance

---

## Caveats

- Intended to be applied during the period of the **COVID-19 pandemic**
- Not a broad scope guidance related to **general** author non-responsiveness
- To be used specifically in instances where it would be
  - **irresponsible** to *hold* the data
  - **non-transparent** to exclude an active author



# ISMPP Official Guidance

16.80% of survey respondents have already applied the guidance to an author situation



**International Society for Medical Publication Professionals**

*Official Guidance on Authorship of Peer-review Publications in Which  
Coronavirus Disease Has Impacted Author Responsiveness*



# Short-term Impact



# Society Perspective

---

**Katy Amberley, BA, MA**  
**Chief Executive**  
**British Society for Haematology**



# Katy Amberley, Chief Executive British Society for Haematology (BSH)

---

- Immediate and biggest effect of COVID-19 on BSH business:
  - Cancellation of 60<sup>th</sup> Annual Scientific Meeting (ASM), 26-29 April 2020
  - Why cancellation not postponement?
  - What can we retrieve from this year's meeting?
- Other effects on BSH:
  - Sudden and swift transition from office to home working
  - Governance issue
  - Journals
  - COVID-19 web resources for members
  - Events due later in the year




# Industry Perspective

**Tyson Tu, PhD**  
**Director, Global Medical Communications,**  
**Vertex**



# Congresses: What is Happening?

## Current Plans of 59 Upcoming Medical Congresses



- MedPage Today: tracking the plans of 59 upcoming medical meetings
- Most (56%) have been cancelled
  - 25% have gone virtual and an additional 15% are “exploring virtual options”
- Only 3 (5%) are still going ahead:
  - EuroPCR, 19-22 May, Paris
  - SLEEP, 13-17 June, Philadelphia
  - AACI CRI, 7-9 July, Chicago

Source: <https://www.medpagetoday.com/infectiousdisease/covid19/85261> (Accessed 16 April 2020)





## Survey: Which of the following has your team experienced regarding changes to congresses? Select all that apply

Answer Choices	Responses
Congress has been cancelled	84.36% (259)
Congress is going virtual	86.97% (267)
Congress has been cancelled, but abstract book will be published	57.98% (178)
Congress has been postponed	77.52% (238)
Status of congress is unclear	68.08% (209)
We have not experienced any issues with congresses to date	0.65% (2)
Other (please specify)	5.21% (16)
Total Respondents	307




## Survey: Has your team taken any of these actions on behalf of authors? Select all that apply

Answer Choices	Responses
Presentation withdrawn from congress	23.40% (62)
Accepted abstract withdrawn from congress	24.91% (66)
Content is being submitted to a different congress	54.34% (144)
Develop journal article instead	40.75% (108)
No actions taken at this time	30.94% (82)
Other	5.66% (15)



# Case Study



- How do we get our data out soonest?
- Do we still go to Congress 1?
- Will Congress 2 allow us submit an encore abstract?
- If we present at both congresses, which is the encore?



## Agency Perspective

---

**Alex Torre-Tasso, BA**  
**Global Business Unit Head**  
**Envision Pharma Group**



# COVID-19 impact on publications to date

ISMPP Survey feedback consistent with Envision survey  
conducted across > 130 pub plans we support

## CONGRESSES

### ✓ MID MARCH – MID MAY

#### Congress Cancellations and Postponements

- Cancellations happened with smaller, regional meetings
- For postponements authors for most part awaiting new date but some withdrawals

### ✓ MID MAY -> JULY

#### Virtual or Postponement

- Just starting to gain experience with congress
- New opportunities in audio/video recording and laying out podium and poster presenters
- Decisions come down to timing, approval realities and cost

### ✓ AUGUST ->

TBD

## MANUSCRIPTS

- ISMPP guidance provided
- For the most part manuscript development continues and is not being expedited if congress is postponed or cancelled
- However, as expected, many authors are requesting extensions which is slowing the pace of overall development



# Projecting year-end publications impact

While publications continue, so too will the impact of COVID-19



## Congresses

Virtual options continue



*If congress is F2F expect fewer attendees given apprehension in traveling so expect some form of virtual component*



*Expect continued presentation support (either virtual or F2F)*



*Near term virtual congress experiences will impact end of year virtual options – successful mechanisms will be brought forward*

Some reductions in congress presentations

Likely fewer submissions to regional/smaller congresses if they occur



## Journals

*Expect continued slight delays in manuscript submissions*

*Expect some manuscripts going straight to journal submission*


*Expect to see an increase in usage of publisher digital options*



## Panel Discussion

---

Carolyn Hustad, PhD  
Associate Vice President  
Merck & Co., Inc



# Panel Questions

---

1. How should authorship practices be adapted when authors of congress presentations are nonresponsive?
2. How may the formats of posters and presentations change for virtual meetings?
3. Are there specific considerations when congress presentations are available open access?
4. When a congress is cancelled, will most authors still want to publish their abstracts in the meeting proceedings, or will they retract their abstracts and wait for an opportunity to present their findings “live?”





# Future Considerations

---



# Publisher Perspective

---

**Maria Khan, BSc**  
**Senior Editorial Director**  
**Wiley**

# Wiley: Publisher Perspective

- Helping customers adapt to digital-only world
- Publishing journal articles and maintaining standards
- Supporting digital access
- Making it easier and faster for authors to publish


**Wiley Online Library** | Coronavirus Resources & News

---

[Free Access](#)

**Global guidance for surgical care during the COVID-19 pandemic**  
 COVIDSurg Collaborative

BJS (British Journal of Surgery) | DOI: 10.1002/bjs.11646



During pandemics, surgical services need to balance supporting the whole hospital response and minimizing the risk of nosocomial spread of COVID-19 against continuing care for acute surgical conditions and managing urgent elective surgery. This article identifies the key considerations that should be included in pandemic plans for surgical services. Best available advice

**Regional Government Links**

- [China CDC Weekly](#)
- [CDC Statistics on the Epidemic](#)
- [US CDC \(Centers for Disease Control\)](#)
- [Australia Department of Health](#)
- [Government of Canada](#)
- [European Centre for Disease Prevention and Control](#)
- [Ministry of Solidarity and Health, France](#)
- [Singapore Department of Health](#)
- [United Kingdom](#)



## The Future?

Jason Gardner, BSc, PhD, ISMPP CMPP™  
Head of Scientific Services  
CMC Connect, McCann Health Medical  
Communications




It depends...

How long  
will we be in  
lockdown?

Will there be  
future repeated  
lockdowns?

Which sectors  
will be able to  
re-open and  
when?



# Survey: Impact of Data Availability

Answer choices	Responses
Enrollment in clinical studies slowed/halted, or CTP were disrupted	69% (147)
Physical labs closed or researchers sent home	26% (56)
Non-availability of statistical support	29% (61)
Supporting new pubs related to COVID-19	18% (39)
Other	12% (25)




# Survey: What do you think the long-term impact of COVID-19 might be on pubs?





# Force for positive change in publications





# Publications need to address the 'COVID-19 factor'



Missing data;  
delayed reporting;  
affect adverse  
event reporting;  
efficacy outcomes



Greater focus  
on RWE



Stratification by  
COVID / non-COVID  
datasets



Clinical trial  
interpretation and  
contextualization




Innovation in future  
technology, and  
scientific and  
clinical research to  
advance medicine



# Panel Discussion

---

**Carolyn Hustad, PhD**  
**Associate Vice President**  
**Merck & Co., Inc**



# Panel Questions

---

1. What factors will impact publications budgets in the long term?
2. Preprints are playing an important role in disseminating COVID-19 research rapidly. Do you think this will influence preprint usage to increase for non-COVID-19 research?
3. Will traditional journals become less important?
4. What will happen to future congresses: live, virtual, or a mix?
5. What are the silver linings of this pandemic?



# Final Thoughts

---



**Carolyn Hustad, PhD**  
**Associate Vice President**  
**Merck & Co., Inc**



# The Lasting Impact of COVID-19



OLD WORLD



NEW WORLD



OLD WORLD

NEW WORLD

**BEST of BOTH**

*No matter the circumstances our industry remains committed to ensuring important therapeutic and product information gets properly and ethically communicated to healthcare professionals*



## Q&A

Lisa Baker, PhD,  
ISMPP CMPP™  
Freelance Medical  
Writer

Carolyn Hustad, PhD  
Associate Vice President  
Merck & Co., Inc



# Questions

- To ask a question, please type your query into the Q&A box
- To ensure anonymity and that all presenters receive your question, please choose the drop down box option:

**"Host & Presenters"**

Otherwise, all audience members will be able to see your submitted question

- We will make every effort to respond to all questions

1. Click on the question mark to view the Q&A box

2. Type your question into the Q&A box and SEND

**NOTE: Make sure you send your question to: "Host & Presenters"**



The screenshot shows the Zoom meeting interface. At the top, the 'Participants' panel is visible. A red box highlights a question mark icon in the top right corner of the meeting window. A red arrow points from this icon to the Q&A box. The Q&A box is open, showing a question from 'Laine Capaccio' at 10:22 AM: 'Q: can you see my q&a?'. Below the question, there is an 'Ask:' dropdown menu with 'Host & Presenters' selected. A red arrow points from the Q&A box to the 'Send' button. Another red arrow points from the 'Send' button in the Q&A box to the 'Send' button in the chat area.






# Upcoming ISMPP U's – 16<sup>th</sup> Annual Mtg Previews!

Don't miss your opportunity to sample the excellent content from the upcoming ISMPP virtual Annual Meeting

DATE	TOPIC	FACULTY
May 20, 2020 	<i>Bite-size content: reaching physicians in a time-poor era of information overload</i>	Richard Ashdown, McCann Health Medical Communications  Joanne Walker, Future Science Group  Beth Whann, Pfizer  Mary Gaskarth, CMC Affinity
May 27, 2020 	<i>Data privacy protection: Which wayforward?</i>	Jon Bigelow, Coalition for Healthcare Information



# Thank You for Attending!

---

- We hope you enjoyed today's presentation.
- **Please check your email for a link** to a survey that should take only a few minutes to complete.
- We depend on your feedback and take your comments into account as we develop future educational offerings. Thank you in advance for your participation!



# Survey Results

---

Backup



# Q1: To what extent has your team's workflow and publication planning been disrupted recently by external factors related to the coronavirus pandemic?

Answered: 334 Skipped: 0

Answer Choices	Responses
Greatly disrupted	19.46% (65)
Moderately disrupted	42.22% (141)
Somewhat disrupted	32.63% (109)
Not affected at all	5.69% (19)
Total Respondents	334



## Q2: Which of the following has your team experienced regarding changes to congresses? Select all that apply

Answered: 307 Skipped: 27

Answer Choices	Responses
Congress has been cancelled	84.36% (259)
Congress is going virtual	86.97% (267)
Congress has been cancelled, but abstract book will be published	57.98% (178)
Congress has been postponed	77.52% (238)
Status of congress is unclear	68.08% (209)
We have not experienced any issues with congresses to date	0.65% (2)
Other (please specify)	5.21% (16)
Total Respondents	307



### Q3: Which of the following has your team experienced recently because of changes in planned congresses? Select all that apply.

Answered: 266 Skipped: 68


Answer Choices	Responses
Poster/oral presentation was cancelled completely	65.04% (173)
Poster/oral presentation was postponed to a later date (congress was rescheduled)	72.56% (193)
Poster/oral presentation to be transitioned to a virtual format	85.34% (227)
Additional audio/video content developed to accompany a virtual poster/oral presentation	45.86% (122)
Simultaneous congress presentation and journal publication is no longer a possibility	20.30% (54)
Other (please specify)	5.26% (14)
Total Respondents	266



## Q4: Has your team taken any of these actions on behalf of authors? Select all that apply.

Answered: 265 Skipped: 69

Answer Choices	Responses
Poster/oral presentation withdrawn from congress	23.40% (62)
Accepted abstract withdrawn from congress	24.91% (66)
Content is being submitted to a different congress	54.34% (144)
It was decided to develop the content as a journal article instead of presenting at a congress	40.75% (108)
No actions have been taken on behalf of authors at this time	30.94% (82)
Other (please specify)	5.66% (15)
Total Respondents	265



## Q5: Which do your authors seem to prefer?

Answered: 232 Skipped: 102

Answer Choices	Responses
Allowing the original abstract to be published despite a cancelled congress	56.90% (132)
Submitting the abstract to a new congress	28.45% (66)
Other (please specify)	14.66% (34)
Total Respondents	232





**Q6: If your team is working with authors who want to withdraw their abstract from a meeting that was cancelled or postponed, how was the issue resolved? Select all that apply.**

Answered: 255 Skipped: 79

Answer Choices	Responses
The congress allowed the abstract to be withdrawn	30.20% (77)
The congress stated the abstract could not be withdrawn and would be published as planned	7.45% (19)
The new intended congress modified its policies so our authors could submit their content despite previous publication of the abstract	17.65% (45)
N/A	58.04% (148)
Other (please specify)	4.71% (12)
Total Respondents	255



## Q7: Has your team encountered questions about embargo policies, as related to a planned journal publication, after a congress was canceled or postponed?

Answered: 259   Skipped: 75

Answer Choices	Responses
Yes	45.95% (119)
No	54.05 (140)
Total Respondents	259



# Q8: How were questions about an embargo policy resolved? Select all that apply.

Answered: 248 Skipped: 86

Answer Choices	Responses
The congress released its embargo policy after a meeting was cancelled	14.11% (35)
The congress modified its embargo policy after a meeting was postponed	18.15% (45)
The congress modified its embargo policy, even though a virtual meeting was scheduled in its place	14.92% (37)
The congress did not modify its embargo policy	16.53% (41)
The congress has not provided information at this time	29.44% (73)
N/A	47.58% (118)
Other (please specify)	0.40% (1)
Total Respondents	248



## Q9: Which of the following has your team experienced recently regarding journal submissions? Select all that apply.

Answered: 248 Skipped: 86

Answer Choices	Responses
Journal responded with peer review comments, but deadline to submit revisions is challenging to meet under the circumstances	23.39% (58)
Journal delayed sending out manuscript for peer review	14.11% (35)
Journal delayed first response after submission (possibly because of nonavailability of reviewers)	20.56% (51)
Manuscript has been accepted, but publication has been delayed	12.10% (30)
We have not experienced any issues with journals to date	53.23% (132)
Other (please specify)	9.27% (23)
Total Respondents	248



# Q10: In working with authors since the pandemic began, has your team experienced any of the following? Select all that apply.

Answer Choices	Responses
An author has become nonresponsive	56.47% (144)
An author has indicated they will need more time to review a publication	69.41% (177)
An author has withdrawn from an ongoing publication project	6.67% (17)
An author has withdrawn from a future planned publication	6.67% (17)
An authorship invitation was rescinded because the intended author was nonresponsive	3.53% (9)
A nonresponsive author was removed from a publication and acknowledged as a contributor	5.10% (13)
A nonresponsive author that met ICMJE Criteria 1 & 2 was left on the byline with remaining author approval, and the abstract/manuscript was submitted with an accompanying statement to the journal/congress	10.59% (27)
We have not experienced unusual issues with authors to date	16.47% (42)
Other (please specify)	6.67% (17)
Total Respondents	255



## Q11: Has your team considered alternate plans for manuscript submissions? Select all that apply.

Answered: 249 Skipped: 85

Answer Choices	Responses
Submitting to a preprint server	8.43% (21)
Submitting to a rapid review journal	18.47% (46)
Submitting to an open access journal	15.26% (38)
We have not considered alternate plans at this time	69.88% (174)
Other (please specify)	4.02% (10)
Total Respondents	249



## Q12: ISMP recently released an “Official Guidance on Authorship of Peer-review Publications in Which Coronavirus Disease Has Impacted Author Responsiveness.” Were you aware of this document?

Answered: 256 Skipped: 78

Answer Choices	Responses
I have read this guidance	53.91% (138)
I applied the guidance to an author situation	16.80% (43)
I’m aware this guidance was issued, but it is not relevant to my work	1.56% (4)
I was aware this guidance was issued, and plan to read it	12.50% (32)
I was not aware this guidance was released	15.23% (39)
Total Respondents	256



# Q13: Which of the following has your team experienced recently regarding project timelines because of data availability? Select all that apply.

Answered: 213 Skipped: 121

Answer Choices	Responses
Data availability has been affected because enrollment in clinical studies has slowed or been halted, or clinical trial protocols were disrupted	69.01% (147)
Data availability has been affected because physical laboratories are closed, or researchers were sent home	26.29% (56)
Data availability has been affected because of nonavailability of statistical support	28.64% (61)
Our team has been asked to support new publications relating to the coronavirus/COVID-19	18.31% (39)
Other (please specify)	11.74% (25)
Total Respondents	213






**Q14: Have you experienced other impacts on your publication planning because of the Coronavirus (COVID-19) pandemic? Please share them with us.**

---

- This question was a text box format. Please see responses in speaker notes



## Q15: What do you think the long-term impact of Coronavirus (COVID-19) might be on medical publishing?


---

- This question was a text box format. Please see responses in speaker notes



# Resources


---



# Resources

---

- [COVID-19: What's Cancelled, What Isn't](#)
- [Quick retraction of a faulty coronavirus paper was a good moment for science](#)
- [How to Create an APA Style Reference for a Canceled Conference Presentation](#)
- [#better poster/poster 2.0](#)
- [Speaker Tips for Making your Live Presentation Successful On-Demand](#)



# Resources, con't


---

- [ISMPP U – Visual Medical Communications \(Jan 2020\)](#)
- [ISMPP U – Open Access and Medical Publishing \(Jan 2019\)](#)
- [AMWA - Communicating Real-World Evidence in the Medical Literature](#)
- [Virtual Meetings: Virtually All You Need to Know!](#)
- [What I Would Like You to Know: A Real-World Evidence Expert's Perspective](#)



# Faculty Bios


---



# Speakers

---

- **Katy Amberley**, Chief Executive, British Society for Haematology
- **Jason Gardner**, Head of Scientific Services, CMC Connect, McCann Health Medical Communications
- **Carolyn Hustad**, Associate Vice President, Merck & Co., Inc
- **Maria Khan**, Senior Editorial Director, Wiley
- **Rob Matheis**, President & CEO, ISMPP
- **Alex Torre-Tasso**, Global Business Unit Head, Envision Pharma Group
- **Tyson Tu**, Director, Global Medical Communications, Vertex
- **Chris Winchester**, Chief Executive Officer, Oxford PharmaGenesis




# Faculty: Katy Amberley

---

Katy Amberley graduated with a BA in French and Spanish and obtained her Master's degree in Medieval Studies. She is Chief Executive at the British Society for Haematology (BSH) the UK's biggest professional organisation for doctors and other healthcare professionals who specialise in Haematology. The Society provides clinical guidelines; holds an Annual Scientific Meeting in April and education events across the year; hosts online educational resources; runs a substantive grants programme and co-publishes the British Journal of Haematology and EJHaem with Wiley's. Katy holds financial and legal responsibility for the BSH's operational performance and the delivery of the Board-approved strategic and is supported by a small, dedicated team of 11 staff.






# Faculty: Jason Gardner

---


Jason Gardner holds the position of Head of Scientific Services at CMC Connect, McCann Health Medical Communications. Jason has an honours degree in biological sciences, a doctorate in neuroscience, and he is a Certified Medical Publication Professional. Jason began his career working in the Global Medical Affairs and Global Clinical Development divisions of major UK- and Swiss-based pharmaceutical companies. During this time, he forged effective partnerships with several medical communications agencies to develop and implement medical communication strategies and publication plans for various products across multiple indications. Since joining CMC in 2010, Jason has had the opportunity to also experience the delivery of such outputs from an agency's perspective. At CMC Connect, he leads the scientific team, always striving to achieve excellence and innovation while, at the same time, ensuring efficiency, transparency and compliance. Jason sits on the McCann Health Global Scientific Council, which aims to make a meaningful difference in areas of need in medical science. Jason is also a member of The MAP Working Group, the team driving the topics covered in the ISMPP online newsletter.



## Faculty: Maria Khan

---

Maria Khan is Senior Editorial Director for Health Sciences. Maria is responsible for the strategic development, management and financial performance of Wiley's portfolio of society-owned and proprietary journals in Health Sciences globally, and has partnered extensively with organisations in medicine throughout her career. Maria is based in Oxford and has served Blackwell and Wiley in numerous editorial capacities in Health Sciences over her 25-year publishing career. She has extensive experience in journals, books, and digital publishing, including many in collaboration with international learned societies, associations and colleges.




# Faculty: Rob Matheis

---

**Rob Matheis** has a long tenure within scientific and medical communications and has been an integral part of ISMPP for more than a decade. He joined ISMPP in July of 2019 from his role as the Executive Director and Head of Global Scientific Communications at Celgene Corporation. Previously, he was Senior Director of Evidence Based Medical Communications at Sanofi. Rob began his ISMPP journey as inaugural Chair of the ISMPP Credentialing Board of Trustees, with oversight of examination development and establishment of credentialing criteria. He also served as the 7th President of the ISMPP Board of Trustees. During his tenure, Rob was an influential champion for transitioning ISMPP governance to a permanent board-appointed President and CEO. Most recently, Rob has been Chair of the ISMPP Global Transparency and Trends Committee and a Workstream Lead for the ISMPP Authorship Selection Best Practices Task Force.


His professional interests include establishing the value proposition for medical affairs and enriching the role of medical publication professionals to include medical communication capabilities. Dr. Matheis is a licensed clinical psychologist with specializations in behavioral statistics, neuropsychology, and organizational psychology. He is well-published with an extensive bibliography covering brain and spinal cord injury, multiple sclerosis, and alternative medicine. Outside of work, Rob enjoys spending time with his family, staying active, and volunteering with various community organizations.



# Faculty: Alex Torre-Tasso

---

Alex joined Envision Pharma Group in 2004 when the organization was 15 individuals and now 16 years later is closing in on 800 employees. Prior to joining Envision Pharma Group, Alex spent 15 years in medical advertising, managing plans across a variety of blockbusters including Lipitor. Over the past 16 years while at Envision Pharma Group, Alex's role within the organization has grown from VP, Account Director to Divisional Lead to now overseeing a variety of divisions and departments as a Global Business Unit Head. Alex has two decades of experience managing and leading a variety of publication and medical communication plans. Alex received a BA from St Lawrence University.




# Faculty: Tyson Tu

---

Tyson is a Director in Global Medical Communications at Vertex Pharmaceuticals, leading a team of medical communications professionals with responsibilities in publication and communication strategy and execution. He was previously Head of Scientific Communications at Alkermes, responsible for building a world-class scientific communications team and establishing quality, efficient, and compliant processes and procedures. Between these roles and others, Tyson has over 16 years of experience in Medical Communications, including agency and industry roles that spanned publication planning, scientific communications strategy (including medical communications and medical information), and execution across all aspects of scientific communications.


Tyson received his PhD in Neuroscience from SUNY Upstate Medical University and completed a postdoctoral fellowship at the Indiana University School of Medicine.



# Faculty: Chris Winchester

---

Chris Winchester is CEO of Oxford PharmaGenesis, an award-winning HealthScience communications consultancy with over 300 employees in Oxford, London, Cardiff, Cambridge, Basel, Melbourne and Philadelphia. He is Past Chair of the International Society for Medical Publication Professionals, Co-foundewr of Open Pharma, and a Director of Oxford Health Policy Forum. Chris believes that accurate and timely communication plays a vital role in evidence-based medicine. and publishes and peer reviews original research and systematic reviews in this area and beyond ([see https://orcid.org/0000-0003-3267-3990](https://orcid.org/0000-0003-3267-3990)). He is proud of the partnership between Oxford PharmaGenesis and Evidence Aid, a global charity that is actively collating and disseminating the best available evidence on the management of COVID-19.



## Moderator: Carolyn Hustad

---

Carolyn Hustad has been with Merck & Co., Inc. since 2001, starting as a medical writer, then progressing through roles of increasing responsibility until assuming leadership of the Global Scientific & Medical Publications department in 2016. She has a BS in Chemistry/Marine Science from the University of Miami and a PhD in Biochemistry and Molecular Biology from the University of Southern California, where she studied epigenetic regulation of gene expression. She has been a member of ISMPP since it began [Merck was a founding member company] and is also a member of the steering committee of Medical Publishing Insights and Practices (MPIP).



# ISMPP University

## Coronavirus (COVID-19): Its Impact on Publication Planning

April 29, 2020



Webinar will begin  
promptly at:  
11 AM ET / 4 PM GMT